Hantz Financial Services Inc. Has $4.50 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Hantz Financial Services Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,323 shares of the biopharmaceutical company’s stock after selling 1,823 shares during the quarter. Hantz Financial Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $4,503,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Mediolanum International Funds Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $11,389,000. iA Global Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares in the last quarter. Perpetual Ltd bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $2,004,000. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals by 24.2% in the third quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock valued at $54,248,000 after buying an additional 23,168 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,775 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total transaction of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares of the company’s stock, valued at approximately $7,483,834.44. This represents a 7.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the sale, the chief executive officer directly owned 98,628 shares in the company, valued at $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 21,255 shares of company stock valued at $6,930,337. 0.86% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on ALNY shares. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Finally, Needham & Company LLC cut their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $297.45 on Tuesday. The company’s fifty day simple moving average is $310.76 and its 200-day simple moving average is $358.07. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The firm has a market cap of $39.71 billion, a PE ratio of 81.27 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12 month low of $284.19 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.